An Evaluation of Nefopam Hydrochloride's Therapeutic Effectiveness in Treating Lumbar Disc Prolapse Patients in a Secondary Care Hospital

In the trial, patients with lumbar disc prolapse will have their effectiveness with Nefopam HCL and Etodolac.

In this study, we assessed the efficacy of 30 mg of nefopam hydrochloride in lumbar disc prolapse patients. Nefopam is a non-opioid analgesic drug used to treat postoperative pain. Mechanism of action is inhibiting the re-uptake of serotonin and norepinephrine.

The study design was a prospective observational study. The study was conducted at Sai Nursing Home, Yemmiganur, Kurnool, Andhra Pradesh, India. The study period was from August 2019 to January 2020.

Measuring pain intensity in the patients of Nefopam hydrochloride drug therapy in lumbar disc prolapse patients shows that only 13% of patients have worse pain, 10% have severe pain. In this study, different age groups of patients were studied as follows: 21 patients in 20–30 years of age, 31 patients in 30–40 years of age, 37 patients in 40–60 years of age, and 11 patients in 60–80 years of age The percentage of pain relief from Nefopam hydrochloride drug therapy is as follows: 23 patients in 10–20%, 16 patients in 20–40%, 38 patients in 40–60%, 16 patients in 60–80%, and 7 patients in 80–100%. Assessing pain intensity in a number of patients after nefopam hydrochloride drug therapy is as follows: 10 patients have no pain, 28 have mild pain, 34 have moderate pain, 15 have severe pain, and 13 have the worst pain.

The present data indicate that nefopam has a favourable safety profile in relation to many systemic organs in patients who undergo lumbar disc prolapsed. Nefopam hydrochloride's analgesic effectiveness was proven in the current study's low back pain patients. In cases of mild, moderate, severe, and worst-case pain, nefopam performs better. Nefopam exhibits high effectiveness.